Enhancing Treatment in Persistent Glioblastoma through AGuIX Nanoparticles for Precision Radiotherapy (NanoGBM-Precision): A Phase II, monocenter, open-label, single-arm, no-profit clinical trial.
Latest Information Update: 16 Mar 2022
At a glance
- Drugs Gadolinium chelated polysiloxane based nanoparticle (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms NanoGBM-Precision
- 16 Mar 2022 New trial record